StockMarketWire.com - Shield Therapeutics said it had recorded positive results from a clinical trial of its iron replacement therapy Feraccru.

The AEGIS-H2H clinical trial compared Feraccru to Ferinject, or FCM, the market-leading intravenously delivered iron replacement therapy.

Primary analysis of the study had shown that response to Feraccru at 12 weeks was within 9% of the response seen with FCM and within the 20% limit required by the study protocol to confirm non-inferiority.

More detailed analyses of the data would be presented at Shield's upcoming presentation of its preliminary results for 2018, scheduled for early April 2019.

'In a challenging phase IIIb clinical study, in which Feraccru has been tested against Ferinject, the standard of care for patients who cannot tolerate or are unwilling to take salt-based oral iron therapies, orally delivered Feraccru has demonstrated it is non-inferior to IV iron therapy in treating iron deficiency anaemia,' chief medical officer Mark Sampson said.

'These data enhance the treatment options for such patients as they demonstrate that Feraccru offers a well-tolerated and effective therapy, which can benefit patients in both the short and long term.'


At 8:16am: [LON:STX] Shield Therapeutics Plc share price was +13.25p at 67.5p



Story provided by StockMarketWire.com